At 22nd Century, our important mission is straightforward: to reduce the harm caused by smoking.

To this end, our proprietary genetic engineering technology and plant breeding expertise allow us to control the level of nicotine (and other nicotinic alkaloids) in the tobacco plant. As a result, we are able to grow tobacco with up to 97% less nicotine than conventional tobacco – as well as tobacco plants with relatively high nicotine levels. The applications for this technology are extraordinary; our very low nicotine tobacco has demonstrated remarkable efficacy as a smoking cessation aid. On the other hand, for smokers who do not wish to quit, our high nicotine tobacco enables us to produce a cigarette with what we believe is the world’s lowest tar-to-nicotine ratio.

22nd Century is actively seeking strategic business relationships with companies that share our mission of reducing the harm caused by smoking.


We welcome opportunities to partner with pharmaceutical, nutraceutical, and/or tobacco companies where our collaborators possess unique expertise in product development and commercialization.

To explore how your company might partner with 22nd Century, please contact us at:


We have secured a significant portion of our patent portfolio through in-licensing. Since 1998, we have had multiple R&D agreements with North Carolina State University (”NCSU”) resulting in exclusive worldwide in-licenses to us for various patented technologies relating to the regulation of nicotine in the tobacco plant. Other R&D partners with similar in-licensing arrangements with us relating to the regulation of nicotine in the tobacco plant have included the National Research Council of Canada, Plant Biotechnology Institute in Saskatoon, Canada (“NRC”) and the Nara Institute of Science and Technology in Nara, Japan (“NAIST”). In August 2014, we also entered into a commercial in-license agreement with Precision Plant Sciences, Inc. relating to technology to be used in the tobacco plant and the cannabis plant, and in September, 2014 we entered into a sublicense agreement with Anandia Laboratories, Inc. for the in-licensing of technology relating to the regulation of cannabinoids in the cannabis plant. In December 2014, we purchased all of the patents and patent applications that we previously licensed from NRC.

We encourage companies or research institutions to contact us for an overview of available licensing opportunities at:


We are actively seeking a joint venture partner or licensee to fund the Phase III clinical trials for our X-22 smoking cessation aid in development. Six independent clinical trials (five Phase II trials and one Phase III trial treating an aggregate of 2,438 total smokers) that utilized cigarettes made from 22nd Century’s proprietary tobacco have all demonstrated efficacy. Indeed, each of these independent clinical trials using Very Low Nicotine Content (VLNC) cigarettes showed increased quit rates, whether VLNC cigarettes were used alone or used concurrently with other smoking cessation products.

For more information about this or other out-licensing or joint venture opportunities, please contact us at:


Thomas L. James, Esq.
Vice President & General Counsel